Overview

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Status:
Unknown status
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Phase:
Phase 2
Details
Lead Sponsor:
Madrigal Pharmaceuticals, Inc.